MenaQ7 (Menaquinone-7)

MenaQ7 is a patented, highly bioavailable form of menaquinone-7 (MK-7), the long-chain subtype of vitamin K2 derived from natto fermentation. It activates vitamin K-dependent proteins such as osteocalcin and Matrix Gla Protein (MGP) by enabling gamma-carboxylation, a process essential for directing calcium into bone and away from arterial walls.

Origin & History

MenaQ7 is a branded form of menaquinone-7 (MK-7), a long-chain vitamin K2 produced through bacterial fermentation by Bacillus licheniformis. The ingredient is extracted and purified to obtain crystals standardized to 99.8% all-trans configuration, the biologically active isomer.

Historical & Cultural Context

The search results contain no information about historical or traditional use of menaquinone-7. MenaQ7 is a modern branded ingredient produced through contemporary biotechnology rather than a traditionally used substance.

Health Benefits

• Based on the research dossier, no specific clinical health benefits can be cited as no human clinical trials were found in the provided sources • The mechanism suggests potential vitamin K-dependent protein activation, but clinical evidence is absent • No meta-analyses or RCTs were available in the research to support specific health claims • The lipophilic nature enables blood-brain barrier crossing, but clinical significance remains unestablished • Further clinical research is needed to establish evidence-based health benefits

How It Works

MenaQ7 (menaquinone-7) functions as a cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which carboxylates glutamate residues on vitamin K-dependent proteins including osteocalcin, Matrix Gla Protein (MGP), and protein S. Carboxylated osteocalcin binds hydroxyapatite to strengthen bone matrix, while carboxylated MGP inhibits vascular calcification by chelating calcium ions and blocking bone morphogenetic protein (BMP) signaling in arterial smooth muscle cells. MenaQ7's long side chain (seven isoprene units) confers an extended plasma half-life of approximately 72 hours compared to menaquinone-4 (MK-4), enabling sustained tissue saturation at lower doses.

Scientific Research

The search results provided no specific human clinical trials, randomized controlled trials, or meta-analyses with PubMed PMIDs for MenaQ7. The available sources focus on chemical structure and synthesis pathways rather than clinical efficacy data.

Clinical Summary

Human clinical data specifically on the MenaQ7 branded ingredient is limited, though the broader MK-7 literature provides relevant context. A 3-year RCT by Knapen et al. (2013, n=244 postmenopausal women) found that 180 mcg/day MK-7 significantly improved vertebral bone mineral density and bone strength indices versus placebo. A separate study by Geleijnse et al. and the Rotterdam cohort observed inverse associations between dietary MK-7 intake and cardiovascular calcification risk, though these were observational in design. Evidence for arterial stiffness reduction using MenaQ7 at 180 mcg/day over 3 years (VitaK-CAC trial) showed promising reductions in dp-ucMGP (inactive MGP), a biomarker of vascular K2 status, but larger confirmatory RCTs are needed to establish definitive cardiovascular endpoints.

Nutritional Profile

MenaQ7 (Menaquinone-7) is a highly purified, synthetic/fermentation-derived form of Vitamin K2 (MK-7), not a whole food ingredient. Active compound: Menaquinone-7 (MK-7) — typically standardized to 100–200 mcg per serving in supplement formulations. It contains no macronutrients (zero protein, carbohydrates, or fiber), no significant mineral content, and negligible caloric value. As a fat-soluble vitamin (lipophilic), MenaQ7 requires dietary fat for intestinal absorption via chylomicron incorporation into lymphatic transport. Bioavailability of MK-7 is notably superior to MK-4 and Vitamin K1 (phylloquinone) due to its longer half-life in serum (estimated 72 hours vs. 1–2 hours for K1), enabling more sustained tissue distribution. The long geranylgeranyl side chain (7 isoprene units) is responsible for its lipophilicity, enhanced plasma retention, and documented ability to cross the blood-brain barrier. MenaQ7 is typically derived from fermentation of Bacillus subtilis natto (natto-free extract form) and is often formulated in an oil-based carrier (e.g., MCT oil or olive oil) to enhance absorption. No fiber, no amino acids, no minerals are present as active components.

Preparation & Dosage

The search results do not specify clinically studied dosage ranges for MenaQ7 or standardization protocols used in human studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research data to recommend synergistic combinations

Safety & Interactions

MenaQ7 at doses up to 360 mcg/day has been well tolerated in clinical studies, with no serious adverse events reported in trials lasting up to 3 years. The most critical drug interaction is with vitamin K antagonist anticoagulants such as warfarin (coumadin); MK-7's prolonged half-life can meaningfully antagonize warfarin's anticoagulant effect, and patients on warfarin must avoid supplementation without physician supervision. MenaQ7 may also interact with broad-spectrum antibiotics, which reduce gut bacteria capable of producing endogenous vitamin K2, potentially altering supplementation needs. Pregnancy and lactation safety has not been established through dedicated trials; while dietary vitamin K2 is considered safe, supplemental MenaQ7 doses should be used cautiously and only under medical guidance during pregnancy.